Pramlintide is used as an adjunct in insulin-treated diabetes. Its glucose-lowering effect is primarily due to which mechanism?

• A Activating insulin receptor tyrosine kinase
• B Inhibiting glycogen phosphorylase in hepatocytes
• C Increasing peripheral glucose uptake via GLUT4 translocation
• D Suppressing glucagon secretion and slowing gastric emptying ✓

Explanation

Pramlintide is a synthetic amylin analog. Amylin is co-secreted with insulin from beta cells. Pramlintide suppresses glucagon secretion, slows gastric emptying, and promotes satiety, thereby reducing postprandial glucose excursions. It does not directly activate insulin receptors or GLUT4 translocation, nor does it inhibit glycogen phosphorylase.

Reference: Katzung Basic and Clinical Pharmacology, 15th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.